Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Bellicum Pharmaceuticals

Bellicum Pharmaceuticals
2004 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
BLCM STOCK SYMBOL
$2.29 SHARE PRICE (As of Friday Closing)
Description

Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy (BPX-501) to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology (BPX-601) to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and T cell receptors (BPX-701) to treat blood cancers and solid tumors.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 2130 West Holcombe Boulevard
  • Suite 800
  • Houston, TX 77030
  • United States

+1 (832) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Bellicum Pharmaceuticals’s full profile, request a free trial.

Bellicum Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.72 - $4.14 $114M $2.10 -$2.45 1.16M 49.9M

Bellicum Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 35,724 49,616 197,522 284,104
Revenue 2,322 1,120 185 388
EBITDA (99,623) (88,778) (85,598) (66,084)
Net Income (110,716) (98,036) (91,779) (69,241)
Total Assets 133,932 121,501 135,528 132,037
Total Debt 44,523 35,963 35,108 20,385
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bellicum Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Bellicum Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Bellicum Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Bellicum Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Bellicum Pharmaceuticals Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cell Medica Venture Capital-Backed London, United Kingdom 00 00000 0000000000 00000
0000000 0000000000 Formerly VC-backed Heidelberg, Germany 000 00000 00000000000 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00.000 00000000000 00.000
00000000 Venture Capital-Backed Tübingen, Germany 000 00000 00000000000 00000
00000 000000000000 Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
To view this company’s complete list of competitors, request access »

Bellicum Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Bellicum Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Bellicum Pharmaceuticals Executive Team (16)

Name Title Board
Seat
Contact
Info
Rick Fair President, Chief Executive Officer & Board Member
Richard Fair Chief Executive Officer & Board Member
Atabak Mokari Chief Financial Officer
Rosemary Williams Chief Accounting Officer & Controller
Gregory Naeve Ph.D Executive

8 Former Executives

You’re viewing 5 of 16 executives. Get the full list »

Bellicum Pharmaceuticals Board Members (11)

Name Representing Role Since Contact
Info
James Brown AVG Ventures Chairman & Board Member 000 0000
James Daly Self Board Member 000 0000
Jon Stonehouse Self Board Member 000 0000
Judith Klimovsky Self Board Member 000 0000
Reid Huber Ph.D Self Board Member 000 0000

4 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »